Sign in

McCormick & Company, Incorporated MKC

Price 53.8 USD
as of 2026-09-03
47/100
Weak
Quality58
Growth42
Balance-sheet strength30
Valuation58
Momentum30
Income78

Composite 47/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Balance-sheet strength ranks 30/100 — a moderate mark against it.

Case for

Income ranks 78/100 — a strong point in its favour. Valuation ranks 58/100 — a slight point in its favour. Quality ranks 58/100 — a slight point in its favour.

Case against

Balance-sheet strength ranks 30/100 — a moderate mark against it. Momentum ranks 30/100 — a moderate mark against it. Growth ranks 42/100 — a slight mark against it.

What the company does McCormick & Company (MKC) manufactures and markets spices, seasoning mixes, condiments, and flavor solutions globally under brands such as McCormick, Frank’s RedHot, and Cholula. Its two segments—Consumer (retail) and Flavor Solutions (foodservice)—serve grocery retailers, e-commerce, and wholesale distributors.

Key financials MKC reports strong profitability with ROE 24.7%, ROA 5.1%, and net margins 21.9%. Revenue grew 16.7% but EPS declined -14.2%. The balance sheet shows debt/equity 0.65 and a current ratio of 0.78, with FCF yield 4.8% and dividend yield 3.5%.

Stock health Sideravia scores MKC 49.8 overall: Quality 60.9, Growth 53.1, Strength 29.4, Valuation 56.8, Momentum 36.5, Income 77.2. Piotroski F-Score is 7/9, indicating solid financial health.

Price vs fair value MKC trades at a discount of 9.70% versus the analyst mean target of 60.62. - Beat-the-market focus in Zacks (2026-08-17) suggests investor appetite for consumer staples plays. - Forward P/E 15.46 vs trailing 9.10 reflects earnings normalization. - RSI(14) 65.80 indicates near-term momentum building.

Looking forward Forward P/E 15.46 and FCF yield 4.8% suggest moderate valuation with steady cash returns. Momentum remains weak over 6m and 12m, offset by strong income metrics.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.